509 related articles for article (PubMed ID: 22077148)
1. Lack of association of outcomes with treatment duration and microbiologic susceptibility data in Clostridium difficile infections in a non-NAP1/BI/027 setting.
Venugopal AA; Riederer K; Patel SM; Szpunar S; Jahamy H; Valenti S; Shemes SP; Khatib R; Johnson LB
Scand J Infect Dis; 2012 Apr; 44(4):243-9. PubMed ID: 22077148
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027.
Pépin J; Valiquette L; Gagnon S; Routhier S; Brazeau I
Am J Gastroenterol; 2007 Dec; 102(12):2781-8. PubMed ID: 17900327
[TBL] [Abstract][Full Text] [Related]
3. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin.
Al-Nassir WN; Sethi AK; Nerandzic MM; Bobulsky GS; Jump RL; Donskey CJ
Clin Infect Dis; 2008 Jul; 47(1):56-62. PubMed ID: 18491964
[TBL] [Abstract][Full Text] [Related]
4. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection.
Citron DM; Babakhani F; Goldstein EJ; Nagaro K; Sambol S; Sears P; Shue YK; Gerding DN
Anaerobe; 2009 Dec; 15(6):234-6. PubMed ID: 19755166
[TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of Clostridium difficile isolates from horses in an intensive care unit and association of disease severity with strain type.
Magdesian KG; Dujowich M; Madigan JE; Hansen LM; Hirsh DC; Jang SS
J Am Vet Med Assoc; 2006 Mar; 228(5):751-5. PubMed ID: 16506942
[TBL] [Abstract][Full Text] [Related]
6. Vancomycin for the treatment of Clostridium difficile Infection: for whom is this expensive bullet really magic?
Pepin J
Clin Infect Dis; 2008 May; 46(10):1493-8. PubMed ID: 18419481
[TBL] [Abstract][Full Text] [Related]
7. [Assessment of susceptibility to metronidazole and vancomycin of Clostridium difficile strains isolated between 1998-2002].
Pituch H; Obuch-Woszczatyński P; Glinka D; Łazińska B; Meisel-Mikołajczyk F; Łuczak M
Med Dosw Mikrobiol; 2003; 55(3):253-8. PubMed ID: 14702667
[TBL] [Abstract][Full Text] [Related]
8. Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid.
Norén T; Wullt M; Akerlund T; Bäck E; Odenholt I; Burman LG
Antimicrob Agents Chemother; 2006 Sep; 50(9):3028-32. PubMed ID: 16940098
[TBL] [Abstract][Full Text] [Related]
9. Clostridium difficile infection in older adults: a review and update on its management.
Kee VR
Am J Geriatr Pharmacother; 2012 Feb; 10(1):14-24. PubMed ID: 22260856
[TBL] [Abstract][Full Text] [Related]
10. The changing face of Clostridium difficile: what treatment options remain?
Shen EP; Surawicz CM
Am J Gastroenterol; 2007 Dec; 102(12):2789-92. PubMed ID: 18042108
[TBL] [Abstract][Full Text] [Related]
11. [Epidemiological study of Clostridium difficile strains isolated in Jean-Verdier-René-Muret hospitals from 2001 to 2007].
Poilane I; Fantinato C; Cruaud P; Collignon A
Pathol Biol (Paris); 2008; 56(7-8):412-6. PubMed ID: 18842360
[TBL] [Abstract][Full Text] [Related]
12. Metronidazole resistance in Clostridium difficile.
Johnson S; Sanchez JL; Gerding DN
Clin Infect Dis; 2000 Aug; 31(2):625-6. PubMed ID: 10987742
[No Abstract] [Full Text] [Related]
13. Tigecycline for the treatment of severe Clostridium difficile infection.
Larson KC; Belliveau PP; Spooner LM
Ann Pharmacother; 2011 Jul; 45(7-8):1005-10. PubMed ID: 21730279
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.
Debast SB; Bauer MP; Sanders IM; Wilcox MH; Kuijper EJ;
J Antimicrob Chemother; 2013 Jun; 68(6):1305-11. PubMed ID: 23420839
[TBL] [Abstract][Full Text] [Related]
15. Update on Clostridium difficile-induced colitis, Part 2.
Reinke CM; Messick CR
Am J Hosp Pharm; 1994 Aug; 51(15):1892-901; quiz 1958-9. PubMed ID: 7942924
[TBL] [Abstract][Full Text] [Related]
16. Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates.
Barbut F; Mastrantonio P; Delmée M; Brazier J; Kuijper E; Poxton I;
Clin Microbiol Infect; 2007 Nov; 13(11):1048-57. PubMed ID: 17850341
[TBL] [Abstract][Full Text] [Related]
17. A retrospective review of metronidazole and vancomycin in the management of Clostridium difficile infection in patients with hematologic malignancies.
Parmar SR; Bhatt V; Yang J; Zhang Q; Schuster M
J Oncol Pharm Pract; 2014 Jun; 20(3):172-82. PubMed ID: 23804627
[TBL] [Abstract][Full Text] [Related]
18. A multicenter-based study on epidemiology, antibiotic susceptibility and risk factors of toxigenic Clostridium difficile in hospitalized patients in southwestern Iran.
Sedigh Ebrahim-Saraie H; Heidari H; Amanati A; Bazargani A; Alireza Taghavi S; Nikokar I; Kalantar K; Motamedifar M
Infez Med; 2018 Dec; 26(4):308-315. PubMed ID: 30555133
[TBL] [Abstract][Full Text] [Related]
19. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
Lancaster JW; Matthews SJ
Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993
[TBL] [Abstract][Full Text] [Related]
20. Clostridium difficile infection at a medical center in southern Taiwan: incidence, clinical features and prognosis.
Chung CH; Wu CJ; Lee HC; Yan JJ; Chang CM; Lee NY; Chen PL; Lee CC; Hung YP; Ko WC
J Microbiol Immunol Infect; 2010 Apr; 43(2):119-25. PubMed ID: 20457428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
